WaveMan
WaveMan · Company
TMCI · Treace Medical Concepts, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TMCI Treace Medical Concepts (TMCI) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001630627
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
68
13F, latest reported quarter

What the filings say about TMCI

Insiders, 180 days
+$1.5M net bought
1 buyer

Treace Medical Concepts insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, TREACE MEDICAL CONCEPTS, INC. insiders bought a net $1.5M of stock across 242 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Treace John T.
Chief Executive Officer
BUY
2026-08-24 SEC
11,000
$47.7K
-5.4%
Context
  • 53 earlier Form 4 trades (code P or S) here by this insider (27 buys, 26 sales), the last on Aug 21, 2026.
  • +19.6% median (+30.6% mean) 90-day return after 23 previous buys.
  • The trade is 0.1% of the 7,404,383 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Treace John T. bought about $47.7K of TMCI on Aug 24, 2026; 68 funds added in the latest 13F quarter.
Treace John T.
Chief Executive Officer
BUY
2026-08-24 SECtraded 2026-08-21
5,000
$21.7K
-5.4%
Context
  • 52 earlier Form 4 trades (code P or S) here by this insider (26 buys, 26 sales), the last on Aug 20, 2026.
  • +19.6% median (+30.6% mean) 90-day return after 23 previous buys.
  • The trade is 0.1% of the 7,393,383 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Treace John T. bought about $21.7K of TMCI on Aug 21, 2026; 68 funds added in the latest 13F quarter.
Treace John T.
Chief Executive Officer
BUY
2026-08-24 SECtraded 2026-08-20
39,944
$177.2K
-5.4%
Context
  • 51 earlier Form 4 trades (code P or S) here by this insider (25 buys, 26 sales), the last on Jun 11, 2026.
  • +19.6% median (+30.6% mean) 90-day return after 23 previous buys.
  • The trade is 0.5% of the 7,388,383 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Treace John T. bought about $177.2K of TMCI on Aug 20, 2026; 68 funds added in the latest 13F quarter.
Treace John T.
Chief Executive Officer
BUY
2026-06-12 SECtraded 2026-06-11
9,891
$40.0K
+16.1%
Context
  • 49 earlier Form 4 trades (code P or S) here by this insider (23 buys, 26 sales), the last on Jun 10, 2026.
  • +22.6% median (+31.2% mean) 90-day return after 22 previous buys.
  • The trade is 0.1% of the 7,348,439 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Treace John T. bought about $40.0K of TMCI on Jun 11, 2026; 68 funds added in the latest 13F quarter.
Treace John T.
Chief Executive Officer
BUY
2026-06-11 SEC
22,887
$92.5K
+12.1%
Context
  • 49 earlier Form 4 trades (code P or S) here by this insider (23 buys, 26 sales), the last on Jun 10, 2026.
  • +22.6% median (+31.2% mean) 90-day return after 22 previous buys.
  • The trade is 0.3% of the 7,376,150 shares held after it.
  • No other insider bought within 30 days.
  • 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Treace John T. bought about $92.5K of TMCI on Jun 11, 2026; 68 funds added in the latest 13F quarter.
242 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 237 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.5M over 180 days
+$246.7K over 90 days · +$1.5M of it by a 10%+ holder
more than 93% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
68 funds bought in last quarter
more than 52% of Medical Devices
Revenue
+1.6% year over year
below 73% of Medical Devices
Margin
-27.7% net margin
below 58% of Medical Devices
Buybacks
no share repurchases reported
Short interest
4.0% of the float short (float per yahoo 2026-10-27) · 8.3 days to cover · settled 2026-10-15
below 53% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TMCI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.0%12M
-82%-54%-27%+1%2025-102025-122026-022026-042026-062026-082026-10 2026-05-28 · Treace John T. bought $184.8K2026-06-01 · Treace John T. bought $178.0K2026-08-20 · Treace John T. bought $177.2K2026-05-14 · Treace John T. bought $161.8K2026-05-27 · Treace John T. bought $143.0K2026-05-13 · Treace John T. bought $120.6K2026-06-10 · Treace John T. bought $118.3K2026-05-12 · Treace John T. bought $93.3K2026-06-11 · Treace John T. bought $92.5K2026-06-10 · Treace John T. bought $59.2K2026-08-24 · Treace John T. bought $47.7K2026-06-11 · Treace John T. bought $40.0K2026-08-21 · Treace John T. bought $21.7K2026-05-26 · Treace John T. bought $12.6K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TMCI: institutional holders (13F)

13F holdings, latest reported quarter
ARMISTICE CAPITAL, LLC
6,364,000 sh
$25.3M
BANK OF AMERICA CORP /DE/
3,305,100 sh
$13.2M
GAGNON SECURITIES LLC
3,029,543 sh
$12.1M
VANGUARD CAPITAL MANAGEMENT LLC
2,028,479 sh
$8.1M
Gagnon Advisors, LLC
1,534,034 sh
$6.1M

Congress trades in TMCI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TMCI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TMCI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$199.0K position · as of 2026-06-30
0.1%
PACE Small/Medium Co Growth Equity Investments
$130.9K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$659.3K position · as of 2026-06-30
0.0%
AVIP BlackRock Advantage Small Cap Growth Portfolio
$57.3K position · as of 2026-06-30
0.0%
Clearwater Select Equity Fund
$211.9K position · as of 2026-06-30
0.0%
AQR Small Cap Multi-Style Fund
$83.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.4M
-$246.4K
$3.1M
-87%
-24%
2024
$6.6M
$1.1M
$3.8M
-60%
-24%
2023
$8.4M
$2.8M
$4.0M
-32%
-28%
2022
$3.6M
$4.3M
$1.5M
+23%
-23%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.5M bought by insiders over 180 days, 68 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

TMCI financials

Revenue growth
+1.6%
XBRL, annual
Net margin
-27.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$205.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-29.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$25.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.87x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.25x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-72.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-30.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-35.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$342.5M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-8.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$212.7M$209.4M$187.1M$141.8M
Gross profit$169.8M$168.3M$151.9M$116.3M
Operating income-$54.2M-$55.7M-$51.4M-$34.8M
Net income-$59.0M-$55.7M-$50.0M-$43.0M
EPS (diluted)-0.93-0.90-0.81-0.77
Operating cash flow-$16.0M-$37.2M-$34.6M-$30.6M
Cash$10.7M$11.3M$13.0M$19.5M
Long-term debt$55.6M$53.3M$53.0M$52.7M
SEC XBRL, fiscal years, as known on 2026-10-28

TMCI Stock Sonar score 6/7 axes

Find similar shapesCompare

TMCI ranks highest on insider conviction (72nd percentile) and institutional and government (52nd), and lowest on growth (27th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
37
Inputs
  • Return on equity-72.0% · 34 pct, sector of 183
  • Return on assets-30.7% · 39 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-35.3% · 37 pct, sector of 188
Financial health
34
Inputs
  • Debt to equity0.87x · 22 pct, sector of 159
  • Cash flow to debt-0.25x · 46 pct, sector of 150
Growth
27
Inputs
  • Revenue growth, YoY+1.6% · 27 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
72
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.5M · 93 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
52
Inputs
  • Funds adding, latest quarter68 · 52 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
36
Inputs
  • Short interest, % of float+4.0% · 54 pct, sector of 241
  • Recalls per $1B revenue, 3y4.70 per $1B · 23 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+14.4% · 31 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TMCI filings, in plain words

Are Treace Medical Concepts insiders buying or selling TMCI?

In the 180 days to 2026-10-28, Treace Medical Concepts insiders were net buyers, a net $1.5M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Treace Medical Concepts insiders were net buyers of TMCI, a net $1.5M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $1.5M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies